-
Results of a large Stanford Medicine study,published Wednesday in The New England Journal of Medicine,finds CAR-T therapies carry a low risk of secondary malignancies not related to the T cells。
-
Although Massachusetts’life sciences job growth increased by just2.5%in2023,the state continues to grow the industry,according to anew MassBioEd report。
-
6/13/2024
Sirnaomics Ltd.,aleading biopharmaceutical company in discovery and development of RNAitherapeutics,announced that the Group has published a major advancement of its novel Oligonucleotide-Chemodrug Conjugate agent。
-
Building on last year’s potential$7billion partnership with Flagship Pioneering,Pfizer and Flagship-founded ProFound Therapeutics will work on discovering new obesity candidates。
-
6/12/2024
Recce Pharmaceuticals Ltd.,the Company developing a new class of synthetic anti-infectives,announced it completed dosing an additional cohort inits Phase I/II UTI/Urosepsis trial,evaluating RECCE®327at fast infusion rates。
-
6/12/2024
Science37 Holdings,Inc.,aleader in enhancing patient access to clinical trials,announced the final enrollment figures from its20-month engagement with a clinical-stage drug development company advancing novelsmall molecule therapeutics forsystemic neuro-immune disorders。
-
6/12/2024
Fulcrum Therapeutics,Inc.®announced upcoming presentations to be made at the 31 st Annual FSHD Society International Research Congress being held June 13-142024 in Denver,Colorado,including an abstract outlining the baseline characteristics of patients enrolled in the Phase3REACH trial of losmapimod in facioscapulohumeral muscular dystrophy。
-
6/12/2024
Quoin Pharmaceuticals Ltd.,aspecialty pharmaceutical company focused on rare and orphan diseases,announced that it has signed a research agreement with The School of Pharmacy at University College Cork,Ireland。
-
6/12/2024
Avidity Biosciences,Inc.announced positive initial AOC1020data from the Phase1/2FORTITUDE™trial demonstrating unprecedented and consistent reductions of greater than50%in DUX4regulated genes,trends of functional improvement,and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy。
-
6/12/2024
Palatin Technologies,Inc.,abiopharmaceutical company developing first-in-class medicines based on moleculate the activity of the melanocortin receptor system,announced the initiation of a Phase2clinical study of bremelanotide for the treatment of obesity。
-
6/12/2024
Biogennix,anosteobiologics company specializing in products for bone graft procedures,has announced the publication of adetailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material。
-
6/12/2024
Shanghai Junshi Biosciences Co.,Ltd announced that the primary endpoints of progression-free survival and overal survival of a multi-center,randomized,open-label,active-controlled phase III clinical study of the company’s product,toripalimab, in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma has met the pre-defined efficacy boundary。
-
6/12/2024
A team of investigators at City of Hope funded by the Prostate Cancer Foundation reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor T cell therapy。
-
6/12/2024
Treating prostate cancer with immunotherapy is currently difficult to do.But preliminary results from a first in-human phase1trial using a chimeric antigen receptor T cell therapy developed by researchers from City of Hope®showed that patients with advanced prostate cancer had minal sideffects and the mulathsing therapeutic activity,according to astudy published in Nature Medicine。
-
6/12/2024
IB Agents,aleading pediatric osteosarcomanonprofit dedicated to Making It Better forits community of patients,caregivers,doctors,and researchers,announced that since its inception in2016,it has awarded over$1.9 million to scientists across the country through its OutSmarting Osteosarcomgrant。
-
6/12/2024
Innovent Biologics,Inc.announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's®84th Scientific Sessions in Orlando from June 21-24。
-
6/12/2024
Alida Biosciences,an innovator in epigenomic research tools,proudly announces the successful completion of a$7.5 million Series A funding round。
-
6/12/2024
Crystal IS,an Asahi Kasei company,announced the successful serial production of 100mm diameter single-crystal aluminum nitride substrates with99%usable area,based on current requirements forUVC LEDs,with manufacturing to take place in the United States。
-
6/12/2024
OBI Pharma,a clinical-stage oncology company,announced the initiation of a Phase1/2clinical trial of OBI-992,an antibody-drug conjugate targeting TROP2,an antigen overexpressed in multiple tumor types。
-
6/12/2024
BellaSeno GmbH,an ISO13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies,announced that10breast scaffold patients and 5pectus patients have successfully passed one-year follow-up in BellaSeno’s Australian clinical trials。